相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Hideaki Ogiwara et al.
CANCER CELL (2019)
Phosphorylation of Tyr-950 in the proteasome scaffolding protein RPN2 modulates its interaction with the ubiquitin receptor RPN13
Casey W. Hemmis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Structural basis for the recognition of K48-linked Ub chain by proteasomal receptor Rpn13
Zhu Liu et al.
CELL DISCOVERY (2019)
RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-κB-Mediated Cell Apoptosis
Guang-Yang Yu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Drug resistance in multiple myeloma
Pawel Robak et al.
CANCER TREATMENT REVIEWS (2018)
Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome
Geeta Rao et al.
FRONTIERS IN CHEMISTRY (2018)
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer
Ravi K. Anchoori et al.
ACS OMEGA (2018)
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
Danielle A. Jandial et al.
GYNECOLOGIC ONCOLOGY (2017)
Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism
Ryan T. VanderLinden et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets
Xiuxiu Lu et al.
NATURE COMMUNICATIONS (2017)
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma
Rosie T. Jiang et al.
JOURNAL OF OVARIAN RESEARCH (2017)
Enhanced Degradation of Misfolded Proteins Promotes Tumorigenesis
Liang Chen et al.
CELL REPORTS (2017)
SynergyFinder: a web application for analyzing drug combination dose-response matrix data
Aleksandr Ianevski et al.
BIOINFORMATICS (2017)
The recognition of ubiquitinated proteins by the proteasome
Guinevere L. Grice et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression
Leah Randles et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma
Y. Song et al.
LEUKEMIA (2016)
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer
Dawid Walerych et al.
NATURE CELL BIOLOGY (2016)
Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor
Kavya Ramkumar et al.
NATURE COMMUNICATIONS (2016)
Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
K. K. Starheim et al.
BLOOD CANCER JOURNAL (2016)
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells
Ruey-Shyang Soong et al.
ONCOTARGET (2016)
Fundamentals of cancer metabolism
Ralph J. DeBerardinis et al.
SCIENCE ADVANCES (2016)
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
Xin Wang et al.
SCIENTIFIC REPORTS (2016)
Structural Plasticity Allows UCH37 to Be Primed by RPN13 or Locked Down by INO80G
Xiang Chen et al.
MOLECULAR CELL (2015)
A High Affinity hRpn2-Derived Peptide That Displaces Human Rpn13 from Proteasome in 293T Cells
Xiuxiu Lu et al.
PLOS ONE (2015)
Redundant Roles of Rpn10 and Rpn13 in Recognition of Ubiquitinated Proteins and Cellular Homeostasis
Jun Hamazaki et al.
PLOS GENETICS (2015)
Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses
Kathleen Coughlin et al.
CLINICAL CANCER RESEARCH (2014)
Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Q. Ping Dou et al.
CURRENT CANCER DRUG TARGETS (2014)
Inherent Asymmetry in the 26S Proteasome Is Defined by the Ubiquitin Receptor RPN13
Dikla Berko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition
Sunita Maharjan et al.
SCIENTIFIC REPORTS (2014)
Mechanism of the Rpn13-induced activation of Uch37
Lianying Jiao et al.
PROTEIN & CELL (2014)
A Novel Bullet Hits the Proteasome
Alexei F. Kisselev
CANCER CELL (2013)
A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer
Ravi K. Anchoori et al.
CANCER CELL (2013)
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity
B. Kobrinsky et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
Marlena S. Fejzo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Michael S. Anglesio et al.
PLOS ONE (2013)
An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens
Gabriella Parma et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy
Yanfen Liu et al.
CELL RESEARCH (2011)
α,β-Unsaturated Carbonyl System of Chalcone-Based Derivatives Is Responsible for Broad Inhibition of Proteasomal Activity and Preferential Killing of Human Papilloma Virus (HPV) Positive Cervical Cancer Cells
Martina Bazzaro et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Potent and Selective Inhibitors of Glutathione S-Transferase Omega 1 That Impair Cancer Drug Resistance
Katsunori Tsuboi et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
Padraig D'Arcy et al.
NATURE MEDICINE (2011)
Stressing the Ubiquitin-Proteasome System without 20S Proteolytic Inhibition Selectively Kills Cervical Cancer Cells
Ravi K. Anchoori et al.
PLOS ONE (2011)
Road to Ruin: Targeting Proteins for Degradation in the Endoplasmic Reticulum
Melanie H. Smith et al.
SCIENCE (2011)
The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
Peter Walter et al.
SCIENCE (2011)
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Annemiek Broyl et al.
LANCET ONCOLOGY (2010)
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
M. Ri et al.
LEUKEMIA (2010)
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
Carol Aghajanian et al.
GYNECOLOGIC ONCOLOGY (2009)
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours
S. Cresta et al.
EUROPEAN JOURNAL OF CANCER (2008)
Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target
Marlena S. Fejzo et al.
GENES CHROMOSOMES & CANCER (2008)
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer
Pedro T. Ramirez et al.
GYNECOLOGIC ONCOLOGY (2008)
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines
Sandra J. Strauss et al.
CANCER RESEARCH (2007)
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis
M Bazzaro et al.
CANCER RESEARCH (2006)
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis
ST Nawrocki et al.
CANCER RESEARCH (2005)
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer
C Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells
JZ Qin et al.
CANCER RESEARCH (2005)
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
AH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Imaging 26S proteasome activity and inhibition in living mice
GD Luker et al.
NATURE MEDICINE (2003)
分享论文
